| Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials M Khunger, S Rakshit, V Pasupuleti, AV Hernandez, P Mazzone, ... Chest 152 (2), 271-281, 2017 | 400 | 2017 |
| Perinodular and intranodular radiomic features on lung CT images distinguish adenocarcinomas from granulomas N Beig, M Khorrami, M Alilou, P Prasanna, N Braman, M Orooji, S Rakshit, ... Radiology 290 (3), 783-792, 2019 | 244 | 2019 |
| Programmed cell death 1 (PD-1) ligand (PD-L1) expression in solid tumors as a predictive biomarker of benefit from PD-1/PD-L1 axis inhibitors: a systematic review and meta-analysis M Khunger, AV Hernandez, V Pasupuleti, S Rakshit, NA Pennell, ... JCO Precision Oncology 1, 1-15, 2017 | 115 | 2017 |
| Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients M Khunger, PD Patil, A Khunger, M Li, B Hu, S Rakshit, A Basu, N Pennell, ... PloS one 13 (10), e0197743, 2018 | 60 | 2018 |
| Safety and efficacy of PD-1/PD-L1 inhibitors in treatment-naive and chemotherapy-refractory patients with non–small-cell lung cancer: a systematic review and meta-analysis M Khunger, P Jain, S Rakshit, V Pasupuleti, AV Hernandez, J Stevenson, ... Clinical lung cancer 19 (3), e335-e348, 2018 | 59 | 2018 |
| Ipilimumab-induced colitis in patients with metastatic melanoma KM De Felice, A Gupta, S Rakshit, S Khanna, LA Kottschade, HD Finnes, ... Melanoma research 25 (4), 321-327, 2015 | 54 | 2015 |
| An integrated segmentation and shape‐based classification scheme for distinguishing adenocarcinomas from granulomas on lung CT M Alilou, N Beig, M Orooji, P Rajiah, V Velcheti, S Rakshit, N Reddy, ... Medical physics 44 (7), 3556-3569, 2017 | 52 | 2017 |
| Extramedullary disease in multiple myeloma R Bansal, S Rakshit, S Kumar Blood cancer journal 11 (9), 161, 2021 | 39 | 2021 |
| Quantitative vessel tortuosity: A potential CT imaging biomarker for distinguishing lung granulomas from adenocarcinomas M Alilou, M Orooji, N Beig, P Prasanna, P Rajiah, C Donatelli, V Velcheti, ... Scientific reports 8 (1), 15290, 2018 | 32 | 2018 |
| Combination of computer extracted shape and texture features enables discrimination of granulomas from adenocarcinoma on chest computed tomography M Orooji, M Alilou, S Rakshit, N Beig, MH Khorrami, P Rajiah, R Thawani, ... Journal of Medical Imaging 5 (2), 024501-024501, 2018 | 29 | 2018 |
| Incidence of pneumonitis with use of PD-1 and PD-L1 inhibitors in non-small cell lung cancer: A systematic review and meta-analysis of trials. M Khunger, V Pasupuleti, S Rakshit, P Jain, PJ Mazzone, J Stevenson, ... Journal of Clinical Oncology 35 (15_suppl), e20647-e20647, 2017 | 28 | 2017 |
| Uncertainty-informed deep learning models enable high-confidence predictions for digital histopathology JM Dolezal, A Srisuwananukorn, D Karpeyev, S Ramesh, S Kochanny, ... Nature communications 13 (1), 6572, 2022 | 21 | 2022 |
| Neutrophil to lymphocyte ratio as a prognostic marker in metastatic gallbladder cancer M Mady, K Prasai, SH Tella, S Yadav, CL Hallemeier, S Rakshit, ... HPB 22 (10), 1490-1495, 2020 | 19 | 2020 |
| Premature clinical trial discontinuation in the era of immune checkpoint inhibitors M Khunger, S Rakshit, AV Hernandez, V Pasupuleti, K Glass, MD Galsky, ... The Oncologist 23 (12), 1494-1499, 2018 | 19 | 2018 |
| Immunotherapy in patients with autoimmune disease S Rakshit, JR Molina Journal of Thoracic Disease 12 (11), 7032, 2020 | 13 | 2020 |
| Meta-analysis of tumor PD-L1 expression as a predictive biomarker of benefit from PD-1/PD-L1 axis inhibitors in solid tumors. M Khunger, S Rakshit, KA Schalper, P Elson, NA Pennell, J Stevenson, ... Journal of Clinical Oncology 34 (15_suppl), 11603-11603, 2016 | 10 | 2016 |
| Pre-treatment hematological markers as a predictive biomarker for survival in patients with non-small cell lung cancer treated with nivolumab. PD Patil, M Khunger, S Rakshit, J Stevenson, NA Pennell, P Elson, ... Journal of Clinical Oncology 35 (15_suppl), 11547-11547, 2017 | 9 | 2017 |
| Durable response to combination of dabrafenib and trametinib in BRAF V600E-mutated non–small-cell lung cancer LM Pervere, S Rakshit, AB Schrock, VA Miller, SM Ali, V Velcheti Clinical Lung Cancer 18 (3), e211-e213, 2017 | 7 | 2017 |
| Computerized textural analysis of lung CT to enable quantification of tumor infiltrating lymphocytes in NSCLC. M Orooji, S Rakshit, N Beig, A Madabhushi, V Velcheti Journal of Clinical Oncology 34 (15_suppl), 11584-11584, 2016 | 7 | 2016 |
| Outcomes of COVID-19 in patients with cancer: a closer look at pre-emptive routine screening strategies Z Xie, AN Saliba, J Abeykoon, U Majeed, DR Almquist, ... JCO Oncology Practice 17 (9), e1382-e1393, 2021 | 6 | 2021 |
